Format

Send to

Choose Destination
See comment in PubMed Commons below
Infect Agent Cancer. 2013 Apr 8;8(1):13. doi: 10.1186/1750-9378-8-13.

c-Met inhibitors.

Author information

1
Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. coolaslam8@hotmail.com.

Abstract

c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes: class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including chemo-, radio- or immunotherapy.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center